Avoiding phagocytosis-related artifact in myeloid derived suppressor cell T-lymphocyte suppression assays

Journal of Immunological Methods

Volumn 440, Issue , 2017, Pages 12-18

  Davis, Ruth J ^a   Silvin, Christopher ^a   Allen, Clint T ^a,b  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Artifact; CD3 28 microbeads; MDSC; Myeloid derived suppressor cells; Phagocytosis; T cell suppression assay

Indexed keywords

CARCINOGEN; CD11B ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CYTOCHALASIN D; GAMMA INTERFERON RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL CULTURE; CELL SELECTION; CELL SUSPENSION; CELL VIABILITY; CYTOMETRY; DILUTION; FLOW CYTOMETRY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; MOUTH CARCINOMA; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; PHAGOCYTOSIS; PHOTOGRAPHY; PRIORITY JOURNAL; REVIEW; SPLEEN; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MODEL; ANIMAL; ARTIFACT; C57BL MOUSE; CELL DEATH; CELL PROLIFERATION; COCULTURE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIXED LYMPHOCYTE CULTURE; MOUTH TUMOR; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; TIME FACTOR; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; ARTIFACTS; CELL DEATH; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE, INBRED C57BL; MOUTH NEOPLASMS; MYELOID-DERIVED SUPPRESSOR CELLS; PHAGOCYTOSIS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TIME FACTORS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85006751487     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2016.11.006     Document Type: Review

References (19)

1. Beury, D.W., Carter, K.A., Nelson, C., Sinha, P., Hanson, E., Nyandjo, M., et al. Myeloid-derived suppressor cell survival and function are regulated by the transcription factor Nrf2. J. Immunol. 196 (2016), 3470–3478, 10.4049/jimmunol.1501785.
2. Cash, H., Shah, S., Moore, E., Caruso, A., Uppaluri, R., Van Waes, C., et al. mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. Oncotarget 6 (2015), 36400–36417, 10.18632/oncotarget.5063.
3. Chen, S., Wang, L., Fan, J., Ye, C., Dominguez, D., Zhang, Y., et al. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 75 (2015), 519–531, 10.1158/0008-5472.CAN-14-2331.
4. Condamine, T., Gabrilovich, D.I., Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 32 (2011), 19–25, 10.1016/j.it.2010.10.002.
5. Dimitrov, J.D., Vassilev, T.L., Andre, S., Kaveri, S.V., Lacroix-Desmazes, S., Functional variability of antibodies upon oxidative processes. Autoimmun. Rev. 7 (2008), 574–578, 10.1016/j.autrev.2008.04.009.
6. Filatenkov, A., Baker, J., Mueller, A.M.S., Kenkel, J., Ahn, G.-O., Dutt, S., et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin. Cancer Res. 21 (2015), 3727–3739, 10.1158/1078-0432.CCR-14-2824.
7. Gabitass, R.F., Annels, N.E., Stocken, D.D., Pandha, H.A., Middleton, G.W., Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 60 (2011), 1419–1430, 10.1007/s00262-011-1028-0.
8. Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 (2009), 162–174, 10.1038/nri2506.
9. Highfill, S.L., Cui, Y., Giles, A.J., Smith, J.P., Zhang, H., Morse, E., et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med., 6(237ra67), 2014, 10.1126/scitranslmed.3007974.
10. Hock, B.D., McKenzie, J.L., Suppression of CD3/CD28 antibody stimulated responses by human granulocytic myeloid-derived suppressor cells: fact or artefact?. Immunol. Lett. 152 (2013), 151–152, 10.1016/j.imlet.2013.05.009.
11. Hock, B.D., Taylor, K.G., Cross, N.B., Kettle, A.J., Hampton, M.B., McKenzie, J.L., Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability. Immunology 137 (2012), 249–258, 10.1111/imm.12004.
12. Judd, N.P., Winkler, A.E., Murillo-Sauca, O., Brotman, J.J., Law, J.H., Lewis, J.S., et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72 (2012), 365–374, 10.1158/0008-5472.CAN-11-1831.
13. Pak, A.S., Wright, M.A., Matthews, J.P., Collins, S.L., Petruzzelli, G.J., Young, M.R., Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1 (1995), 95–103.
14. Quah, B.J.C., Warren, H.S., Parish, C.R., Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2 (2007), 2049–2056, 10.1038/nprot.2007.296.
15. Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203 (2006), 2691–2702, 10.1084/jem.20061104.
16. Sinha, P., Clements, V.K., Ostrand-Rosenberg, S., Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 174 (2005), 636–645.
17. Vasquez-Dunddel, D., Pan, F., Zeng, Q., Gorbounov, M., Albesiano, E., Fu, J., et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 123 (2013), 1580–1589, 10.1172/JCI60083.
18. Weed, D.T., Vella, J.L., Reis, I.M., De la Fuente, A.C., Gomez, C., Sargi, Z., et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin. Cancer Res. 21 (2015), 39–48, 10.1158/1078-0432.CCR-14-1711.
19. Youn, J.-I., Collazo, M., Shalova, I.N., Biswas, S.K., Gabrilovich, D.I., Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91 (2012), 167–181, 10.1189/jlb.0311177.